Stock market analyst Pankaj Jain of Satguru Capital has maintained 'buy' rating on Ankur Drugs & Pharma Ltd stock to achieve a target of Rs 157.

The strict stop loss for the stock should be Rs 144.

Today, the stock of the company opened at Rs 143.45 on the Bombay Stock Exchange (BSE).

The share price has seen a 52-week high of Rs 251 and a low of Rs 116 on BSE.

Ankur Drugs and Pharma Limited is involved in contract fabrication of pharmaceuticals formulations of a range of dosage types to multinational pharmaceutical firms.

Its biz segment comprises pharmaceutical formulations in tabs, caps, liquid orals, oral powder, dry syrups, ointments both fabricated as well as outsourced.

It is into 100% contract manufacturing activity.

Ankur Drugs and Pharma's client list comprise Ranbaxy Labs Ltd, Cipla Ltd, Khandelwal Labs Pvt. Ltd, Makers Lab Ltd, Hetero Healthcare Ltd, Elder Pharma Ltd, Lyka Labs Ltd, Blue cross Labs Ltd, Cadila Labs Ltd, Wockhardt Ltd, Glenmark Pharma Ltd, Parentral Drugs Ltd, Torrent Pharma Ltd, Sandoz (India) Pvt Ltd, Shreya Life Sicences Ltd, Synthiko Formulations and Nicholas Piramal India Ltd.